It also included a time point of>6 months after the second vaccination, as well as other current therapy (such as chemotherapy, chemotherapy plus radiotherapy, endocrine therapy plus abemaciclib to inhibit CDK4/6, and Chinese medicine), and other therapy during the second vaccination (including chemotherapy, pertuzumab and trastuzumab for HER2-positive, and chemotherapy plus pertuzumab and trastuzumab for HER2-positive) among breast cancer patients receiving two vaccination doses (Supplementary Table S6). This evidence concerns the gene ERBB2 and breast carcinoma.